Publications by authors named "Natalia V Chebotareva"
Article Synopsis
- The study investigated the presence of anti-podocyte antibodies, specifically targeting synaptopodin and annexin 1, in patients with nephrotic syndrome to evaluate their role in diagnosing primary podocytopathies like Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS).
- A total of 72 nephrotic syndrome patients were analyzed, alongside 21 healthy individuals, finding higher antibody levels in MCD and FSGS patients compared to the others, indicating their potential use in diagnosis.
- The combined analysis of both antibody types showed significant diagnostic accuracy (sensitivity of 80.9% and specificity of 81.3%), although these antibody levels did not predict how well patients
Glomerulopathies with nephrotic syndrome that are resistant to therapy often progress to end-stage chronic kidney disease (CKD) and require timely and accurate diagnosis. Targeted quantitative urine proteome analysis by mass spectrometry (MS) with multiple-reaction monitoring (MRM) is a promising tool for early CKD diagnostics that could replace the invasive biopsy procedure. However, there are few studies regarding the development of highly multiplexed MRM assays for urine proteome analysis, and the two MRM assays for urine proteomics described so far demonstrate very low consistency.
View Article and Find Full Text PDFArticle Synopsis
- Primary focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) are kidney disorders characterized by damage to podocytes, leading to nephrotic syndrome, but their underlying causes remain unclear.
- A study was conducted to analyze the urinary proteomic profiles of patients with FSGS and MCD, involving 30 FSGS and 9 MCD patients, who were categorized based on disease severity using a scoring system.
- The results identified 22 proteins with significant differences between severe and mild cases of FSGS and MCD, with consistent patterns observed in both initial and targeted analyses, suggesting distinct proteomic signatures for each condition.